Medimabbio

Developer of immunotherapeutics for treating cancer

placeSeongnam-si, Gyeonggi-do, South Korea calendar_todayFounded 2017 groups19 employees language medimabbio.com

Social engagement

Social engagement: 571 social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

16 investors on record; lead investors include KB Investment.

Investor typeCountShare
Venture capital1063%
Private equity16%
Other / undisclosed531%

Recent activity

19 Dec 2025
Event
JPM Week 2026
23 Oct 2025
Recognition
23 Oct 2025
Event
BIO-Europe Fall 2025
Coming soon